NICE has published draft guidance recommending pomalidomide (Imnovid, Celgene) for treating some people with multiple myeloma.  New data, including updated comparisons of pomalidomide with other treatments, was presented as part of this review.

The committee concluded that pomalidomide could be recommended as a clinically and cost effective use of NHS resources in people whose disease had relapsed after 3 previous treatments, including lenalidomide and bortezomib. The NHS has been offered a confidential discount on the drug’s list price. and approx. 630 patients would be eligible for treatment with this drug a year. …..more

 

Leave a Comment